Autopsy report · NCT04260893

Prospective Study To Assess The Safety And Effectiveness Of Tixel Treatment On Dry Eye Symptoms In Asian Patients

“Due to COVID19 adequate study monitoring wasn't possible by the Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 2 months before it stopped.
• 44 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Novoxel Ltd.

Sponsor type

Industry

Conditions

Dry Eye Syndromes; Dry Eye

Interventions

Tixel

Participants

44

Sites

1

Countries

Cambodia

Trials that died the same way

• Correlating the OA Knee Microenvironment to Outcomes After Regenexx-SD Treatment: A Multi-Site Study
  “sponsor discontinued study-impacted by COVID” (80% match in meaning)
• The Georgia Latino AIDS/HIV Diagnosis and Linkage in Youth (GLADLY) Project
  “The study was not able to be completed due to the COVID-19 pandemic.” (77% match in meaning)
• SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
  “Sponsor is not proceeding with study due to budget cuts as a result of COVID-19.” (75% match in meaning)
• Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation
  “Sponsor has terminated study due to COVID-19 related concerns” (75% match in meaning)
• Transgender Therapeutic Support Groups
  “Study unable to be conducted due to COVID.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.